AlphaGrep UK’s Apellis Pharmaceuticals APLS Stock Holding History

AlphaGrep UK’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,120	Closed	-$286K	–	739
2026 Q1	$286K	Sell	7,120 -1,203	-14%	-$25.9K	0.08%	536
2025 Q4	$209K	Buy	+8,323	New	+$195K	0.07%	611

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AlphaGrep UK's APLS Position: Q2 2026 in Review

AlphaGrep UK sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 7,120 shares — an estimated $286K sold.

AlphaGrep UK first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $286K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

AlphaGrep UK reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 7,120 Apellis Pharmaceuticals shares in Q2 2026, an estimated $286K.
AlphaGrep UK first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
AlphaGrep UK's Apellis Pharmaceuticals position peaked at $286K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.